Resources
Learn more about EvaThera, MTTI, and the future of radiopharmaceuticals.
Resources
Learn more about EvaThera, MTTI, and the future of radiopharmaceuticals.
EvaThera Brochure
Innovative, therapeutic, and diagnostic targeted radiopharmaceuticals filling critical gaps in oncologic care.
The EvaThera Story
EvaThera Theranostics are a new generation of Evans Blue-based molecules with strong affinity for albumin.
3 year study shows 86% disease control rate
Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
EBTATE for Imaging and Treatment of Thyroid Cancer
177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
EBTATE Reduces Tumor Size in Patients with NETs
Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study.
EBTATE safety and efficacy in patients with NETs
Peptide Receptor Radionuclide Therapy of Late-stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE
SNMMI 2022: EBTATE safety with and without Amino Acid Infusion
Evaluation of Safety, Biodistribution and Dosimetry of a long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE with and without Amino Acid Infusion
Xiaoyuan Chen, PhD EBTATE Explanatory Video
New treatment proves more effective and less toxic for neuroendocrine tumor patients
EBRGD acts synergistically with checkpoint inhibitors
Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
Ready to learn more?
Reach out to us to learn more about EvaThera, MTTI, and the future of radiopharmaceuticals
© 2023 Molecular Targeting Technologies, INC. All Rights Reserved.
PHONE
610-738-7938
EMAIL